FDA, Obesity and Zepbound

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...